IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Iovance Biotherapeutics raised full-year 2026 revenue guidance from $350–370M to $410–420M (midpoint +$55M, ~15% increase), driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin. The company reported record Q2 2026 product revenue of $99.3M and expanded its authorized treatment center network to ~100 centers with plans for ≥110 by year-end 2026; the raised guidance implies ~60% annual revenue growth.
Why this rating
Guidance raise of $55M midpoint is ~10% of company's $534.8M market cap; strong commercial execution and path to profitability are material. However, company remains pre-profitable and execution risk remains.
Tradability signal
SHORT
conviction 19/100 · expected -0.32% over 4 hrs
SHORT (fade the pop): stock already ran +12.0% on this news, and positive calls in this cell have historically given the pop back (-0.38% over 4 hrs, n=124). Reversion play, lower conviction by design. Exit plan: HARD stop 4.4% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $11.56 ▼ 11.30% | at our read · unknown $13.03 | +10 min · unknown $13.55 ▲ 3.99% | +30 min · unknown $13.87 ▲ 6.45% | +1 hr · unknown $13.28 ▲ 1.88% | +4 hrs · unknown $15.10 ▲ 15.86% |
The stock had already moved +12.74% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.